VT 111

Drug Profile

VT 111

Alternative Names: Serine protease inhibitor-1; SERP-1; VT-111; VT-111a; VT-111b

Latest Information Update: 16 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viron Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Serpins
  • Mechanism of Action Immunosuppressants; Peptide hydrolase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute coronary syndromes

Highest Development Phases

  • No development reported Acute coronary syndromes; Transplant rejection
  • Discontinued Atherosclerosis; Coronary artery restenosis; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-II for Acute coronary syndromes in USA and Canada (IV)
  • 07 Sep 2015 No recent reports on development identified - Preclinical for Transplant rejection (Prevention) in Canada (IV)
  • 20 Dec 2010 VT 111 is available for licensing for cardiac stenting (\www.vironinv.com\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top